- Home
- MPLN vs CHRS Comparison
MPLN vs CHRS Comparison
Compare MPLN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLN
- CHRS
- Stock Information
- Founded
- MPLN 1980
- CHRS 2010
- Country
- MPLN United States
- CHRS United States
- Employees
- MPLN N/A
- CHRS N/A
- Industry
- MPLN Business Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPLN Consumer Discretionary
- CHRS Health Care
- Exchange
- MPLN Nasdaq
- CHRS Nasdaq
- Market Cap
- MPLN 99.9M
- CHRS 100.9M
- IPO Year
- MPLN N/A
- CHRS 2014
- Fundamental
- Price
- MPLN $7.00
- CHRS $1.09
- Analyst Decision
- MPLN Hold
- CHRS Strong Buy
- Analyst Count
- MPLN 2
- CHRS 4
- Target Price
- MPLN $25.00
- CHRS $6.13
- AVG Volume (30 Days)
- MPLN 84.7K
- CHRS 3.4M
- Earning Date
- MPLN 11-05-2024
- CHRS 11-06-2024
- Dividend Yield
- MPLN N/A
- CHRS N/A
- EPS Growth
- MPLN N/A
- CHRS N/A
- EPS
- MPLN N/A
- CHRS N/A
- Revenue
- MPLN $942,614,000.00
- CHRS $304,340,000.00
- Revenue This Year
- MPLN N/A
- CHRS $3.33
- Revenue Next Year
- MPLN $1.07
- CHRS $16.77
- P/E Ratio
- MPLN N/A
- CHRS N/A
- Revenue Growth
- MPLN N/A
- CHRS 44.19
- 52 Week Low
- MPLN $4.80
- CHRS $0.66
- 52 Week High
- MPLN $69.20
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- MPLN 41.66
- CHRS 68.04
- Support Level
- MPLN $4.80
- CHRS $0.70
- Resistance Level
- MPLN $9.15
- CHRS $1.17
- Average True Range (ATR)
- MPLN 0.91
- CHRS 0.11
- MACD
- MPLN -0.14
- CHRS 0.05
- Stochastic Oscillator
- MPLN 49.89
- CHRS 84.31
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.